Beijing Topraise Medical Science & Technology Co. and Beijing WIN-SUM Investment Co. announces continued interest in Vigmed Holding AB (publ) after SEK 45 million investment offer has been turned down

The Investors has on 5 April 2017 presented an Offer of SEK 45 million to the bid committee of Vigmed. The Offer was preceded by discussions between the bid committee and the Investors.

The Offer consisted of two parts, one directed share issue and one convertible loan. In the directed
share issue the investors would subscribe for 27,512,411 shares, for a subscription price of SEK 1 per
share, and under the convertible loan Win-Sum would provide Vigmed with a loan of SEK 17,487,589,
that after three years could be converted to shares in Vigmed with a conversion price of SEK 1 per
share. The total value of the Offer was SEK 45 million that would have been paid in cash to Vigmed in
accordance with the standard procedure for issue of shares and convertibles. Up until such payment
could have been made, the Investors offered a bridge loan of SEK 5 million to Vigmed.

The Offer was neither conditional on any commercial undertaking by Vigmed nor financing. As
conditions for the Offer, the Investors mainly requested to be granted access to a data room to
perform a confirmatory due diligence in Vigmed and that the bid committee would withdraw its
recommendation of the Greiner Bio-One GmbH ("GBO") offer announced on 27 February 2017. If
these conditions had been accepted by the bid committee, the shareholders of Vigmed would have
been given the opportunity to resolve on the Offer at a general meeting of Vigmed. Further, the Offer
was conditional on GBO's offer not being successful.

As manifested by the Offer, the Investors see great potential in Vigmed and believe that an investment
in the company would be profitable for the Investors as well as the current shareholders of Vigmed. In
Topraise and Win-Sum, Vigmed would benefit from having two financially strong and robust
shareholders that can support Vigmed through its current phase and future development as well as
give Vigmed direct access to the Chinese market through their current business and sales network.
The Investors are of course aware of the fact that Vigmed's revenues does not currently finance the
company's business, as explained by the bid committee in its announcement on 10 April 2017, but the
Investors believe that a strong focus on the Chinese market in Vigmed's business greatly would
improve Vigmed's financial position.

Since the Offer has been turned down by the bid committee, the Investors are not prepared to make a
binding undertaking to invest in Vigmed. The Investors' interest in Vigmed however remains and they
will closely monitor the progress of the GBO offer. If the opportunity arises, they look forward to
renewing discussions on an investment in Vigmed.

Introduction to Topraise and Win-Sum
Beijing Topraise Medical Technology Co., Ltd. was established in 2002 and is a fast growing Chinese
company which specializes in Chinese marketing and sales of medicine, medical nutrition and medical
devices. Today, the company has 120 employees and 150 contracting sales representatives allocated
in 20 cities in China. The turnover 2016 was over SEK 392 million. Together with a group of investors,
Topraise develops its business and growth by acquisitions and investments in strategic areas of
importance for Chinese life science. Topraise's already established cooperation with hospitals,
distributors and finance partners in China secures a strong platform for future expansion of the
company. During 2016, Topraise built a manufactory plant in the Guizhou Province.

Beijing WIN-SUM Investment Co., Ltd. is an investment company of a group focused on the health
care industry. The turnover for 2016 of the Win-Sum group was over SEK 2,300 million. The Win-Sum
group has conducted investments in hospitals and in companies in the area of distribution, medical
devices and bio-tech research. Two of the hospitals are:

• Third Affiliated Hospital of Chongqing Medical University (top level university hospital), and
• Danyang No.3 People's Hospital.

Win-Sum has also made the following investments in the health care industry:

• Health exam center in Chongqing China that performs general health checks on customers,
• Hui Ying (Beijing) Bio-tech Co., Ltd., a technology company doing Bio-tech technology research and development,
• Hui Tang (Beijing) Medical technology Co., Ltd., a Medical device distribution company, providing second and third classes medical devices to ten top level hospitals, and
• Beijing WKSP Medical Technology Co., Ltd., a medical devices logistical company, providing medical devices storage and logistic services.

10 April 2017

For additional queries, please contact:
Qingxia Shen, Vice President of Beijing Topraise Medical Technology
Phone: +8615201507656, +46 720 10 18 16
Email: [email protected]

The following documents can be retrieved from beQuoted
Beijing Topraise Pressrelease 2017-04-10.pdf

Important message
This press release is not a public offering to acquire shares in Vigmed and the Investors are not considering making a public offering to acquire shares in Vigmed.

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.